Skip to content
Home/Companies/Biotech/ProTgen
PR

ProTgen

Biotech·United States·Active·2yr hold

ProTgen is a biotech company, headquartered in United States.

Entry
2024
Hold
2yr
Status
Active
Est. EV
–

Who owns ProTgen?

ProTgen is currently owned by Boehringer Ingelheim Venture Fund through Boehringer Ingelheim Venture Fund (2010 vintage), since 2024.

Hand-verified · updated 2026-07-03

Boehringer Ingelheim Venture Fund
Investor
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund · 2010 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Boehringer Ingelheim Venture Fund

Other portfolio companies in the same fund.

Refoxy Pharmaceuticals
Active
BiotechGermany· 2024
SwitchKine
Active
BiotechSwitzerland· 2024
Synthetica Pioneering
Active
BiotechChina· 2024
Aurobac Therapeutics
Active
BiotechFrance· 2023
Glox Therapeutics
Active
BiotechUnited Kingdom· 2023
Obulytix
Active
BiotechBelgium· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings